Kymera Therapeutics, Inc.KYMRNASDAQ
Loading
R&D Expense Growth Recovery in ProgressRecovering
Percentile Rank57
3Y CAGR+16.9%
5Y CAGR-13.9%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+16.9%/yr
Annual compound
5Y CAGR
-13.9%/yr
Recent acceleration
Percentile
P57
Within normal range
vs 5Y Ago
0.5x
Contraction
Streak
2 yr
Consecutive growthRecovering
| Period | Value |
|---|---|
| 2025 | 31.78% |
| 2024 | 27.06% |
| 2023 | 15.12% |
| 2022 | 19.87% |
| 2021 | 120.62% |
| 2020 | 67.14% |
| 2019 | 110.18% |
| 2018 | 0.00% |